Filtered By:
Source: The Lancet Neurology
Condition: Stroke
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 244 results found since Jan 2013.
Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study
Publication date: Available online 27 July 2015 Source:The Lancet Neurology Author(s): Linxin Li, Gabriel S Yiin, Olivia C Geraghty, Ursula G Schulz, Wilhelm Kuker, Ziyah Mehta, Peter M Rothwell Background A third of transient ischaemic attacks (TIAs) and ischaemic strokes are of undetermined cause (ie, cryptogenic), potentially undermining secondary prevention. If these events are due to occult atheroma, the risk-factor profile and coronary prognosis should resemble that of overt large artery events. If they have a cardioembolic cause, the risk of future cardioembolic events should be increased. We aimed to asses...
Source: The Lancet Neurology - July 28, 2015 Category: Neurology Source Type: research
Ischaemic stroke of undetermined cause
Publication date: Available online 27 July 2015 Source:The Lancet Neurology Author(s): Jose M Ferro
Source: The Lancet Neurology - July 28, 2015 Category: Neurology Source Type: research
Pathophysiology, presentation, prognosis, and management of intracranial arterial dolichoectasia
Publication date: August 2015 Source:The Lancet Neurology, Volume 14, Issue 8 Author(s): Fernando Pico , Julien Labreuche , Pierre Amarenco Up to 12% of patients with stroke have intracranial arterial dolichoectasia (IADE) and the basilar artery is affected in 80% of these cases. Diagnostic criteria and prognosis studies of IADE are based on basilar artery diameter, which is a good quantitative marker for the severity of the disease. The pathophysiology is largely unknown, but IADE can be viewed as a common final pathway of arterial wall response or damage in the tunica media due to various mechanisms, such as matrix met...
Source: The Lancet Neurology - July 13, 2015 Category: Neurology Source Type: research
Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke
Publication date: Available online 25 June 2015 Source:The Lancet Neurology Author(s): Bruce C V Campbell , Geoffrey A Donnan , Kennedy R Lees , Werner Hacke , Pooja Khatri , Michael D Hill , Mayank Goyal , Peter J Mitchell , Jeffrey L Saver , Hans-Christoph Diener , Stephen M Davis Background Results of initial randomised trials of endovascular treatment for ischaemic stroke, published in 2013, were neutral but limited by the selection criteria used, early-generation devices with modest efficacy, non-consecutive enrolment, and treatment delays. Recent developments In the past year, six positive trials of endovascular t...
Source: The Lancet Neurology - June 26, 2015 Category: Neurology Source Type: research
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Publication date: Available online 23 June 2015 Source:The Lancet Neurology Background A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease in a multicentre, double-blind, placebo-controlled, futility clinical trial. Methods Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1 mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day pioglitazone, 45 mg...
Source: The Lancet Neurology - June 24, 2015 Category: Neurology Source Type: research
Future directions of acute ischaemic stroke therapy
Publication date: July 2015 Source:The Lancet Neurology, Volume 14, Issue 7 Author(s): Marc Fisher , Jeffrey L Saver For several years, the only therapy with proven efficacy for acute ischaemic stroke was alteplase, which is approved for use within 4·5 h after stroke onset in many countries, but only within 3 h in the USA. However, the recanalisation rate with alteplase is modest. Several trials have shown substantial clinical benefit of neurothrombectomy within 6 h of ischaemic stroke onset, which has initiated a new era of acute stroke therapy. As neurothrombectomy becomes part of standard practice, additional trials ...
Source: The Lancet Neurology - June 9, 2015 Category: Neurology Source Type: research
A call to revolutionise acute stroke care and research
Publication date: July 2015 Source:The Lancet Neurology, Volume 14, Issue 7 Author(s): Peter A G Sandercock
Source: The Lancet Neurology - June 9, 2015 Category: Neurology Source Type: research
Epidemiology, pathophysiology, diagnosis, and management of intracranial artery dissection
Publication date: June 2015 Source:The Lancet Neurology, Volume 14, Issue 6 Author(s): Stéphanie Debette , Annette Compter , Marc-Antoine Labeyrie , Maarten Uyttenboogaart , Tina M Metso , Jennifer J Majersik , Barbara Goeggel-Simonetti , Stefan T Engelter , Alessandro Pezzini , Philippe Bijlenga , Andrew M Southerland , Olivier Naggara , Yannick Béjot , John W Cole , Anne Ducros , Giacomo Giacalone , Sabrina Schilling , Peggy Reiner , Hakan Sarikaya , Janna C Welleweerd , L Jaap Kappelle , Gert Jan de Borst , Leo H Bonati , Simon Jung , Vincent Thijs , Juan J Martin , Tobias Brandt , Caspar Grond-Ginsbach , Manja Klos...
Source: The Lancet Neurology - May 11, 2015 Category: Neurology Source Type: research
Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial
Publication date: Available online 30 April 2015 Source:The Lancet Neurology Author(s): Gregory W Albers , Rüdiger von Kummer , Thomas Truelsen , Jens-Kristian S Jensen , Gabriela M Ravn , Bjørn A Grønning , Hugues Chabriat , Ku-Chou Chang , Antonio E Davalos , Gary A Ford , James Grotta , Markku Kaste , Lee H Schwamm , Ashfaq Shuaib Background Current treatment of ischaemic stroke with thrombolytic therapy is restricted to 3–4·5 h after symptom onset. We aimed to assess the safety and efficacy of desmoteplase, a fibrin-dependent plasminogen activator, given between 3 h and 9 h after symptom onset in patients with ...
Source: The Lancet Neurology - May 1, 2015 Category: Neurology Source Type: research
Desmoteplase for late treatment of stroke: still in the dark
Publication date: Available online 30 April 2015 Source:The Lancet Neurology Author(s): Michael D Hill , Bijoy K Menon
Source: The Lancet Neurology - May 1, 2015 Category: Neurology Source Type: research
Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial
Publication date: Available online 20 April 2015 Source:The Lancet Neurology Author(s): Annette Compter , H Bart van der Worp , Wouter J Schonewille , Jan Albert Vos , Jelis Boiten , Paul J Nederkoorn , Maarten Uyttenboogaart , Rob T Lo , Ale Algra , L Jaap Kappelle Background Patients with a recent vertebrobasilar transient ischaemic attack or ischaemic stroke and vertebral artery stenosis of at least 50% have a high risk of future vertebrobasilar stroke. Stenting of vertebral artery stenosis is promising, but of uncertain benefit. We investigated the safety and feasibility of stenting of symptomatic vertebral artery st...
Source: The Lancet Neurology - April 21, 2015 Category: Neurology Source Type: research
Brain CT signs and the effect of alteplase after stroke
Publication date: Available online 27 March 2015 Source:The Lancet Neurology Author(s): Vincent Larrue
Source: The Lancet Neurology - March 27, 2015 Category: Neurology Source Type: research
Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial
Publication date: Available online 27 March 2015 Source:The Lancet Neurology Background Brain scans are essential to exclude haemorrhage in patients with suspected acute ischaemic stroke before treatment with alteplase. However, patients with early ischaemic signs could be at increased risk of haemorrhage after alteplase treatment, and little information is available about whether pre-existing structural signs, which are common in older patients, affect response to alteplase. We aimed to investigate the association between imaging signs on brain CT and outcomes after alteplase. Methods IST-3 was a multicentre, randomised ...
Source: The Lancet Neurology - March 27, 2015 Category: Neurology Source Type: research
The stroke care revolution
Publication date: Available online 6 March 2015 Source:The Lancet Neurology Author(s): The Lancet Neurology
Source: The Lancet Neurology - March 6, 2015 Category: Neurology Source Type: research
Screening for atrial fibrillation after stroke or TIA
Publication date: Available online 4 March 2015 Source:The Lancet Neurology Author(s): Azmil H Abdul-Rahim , Kennedy R Lees
Source: The Lancet Neurology - March 5, 2015 Category: Neurology Source Type: research
